Better Pharma Dividend Stock: Novartis vs. Merck

The article is constructive on both Merck and Novartis, but gives Novartis a slight edge because of its higher 3.1% forward yield, stronger diversification, and cheaper valuation. Merck remains supported by Keytruda, Winrevair, and Capvaxive, with Keytruda still the world’s best-selling cancer drug, while Novartis is navigating Entresto’s patent cliff better than expected and has multiple billion-dollar products in its lineup. For income investors, the piece argues Novartis has the better dividend profile, with an 84.2% payout increase over the past decade versus Merck’s 93.8%.

Analysis

NVS has the cleaner second-order setup because its cash flow is less exposed to a single asset reset. In pharma, the market usually over-discounts patent cliffs when the replacement set is already visible; here, the key signal is not just revenue durability but that management has enough breadth to keep capital allocation flexible while the cliff rolls off. That makes NVS more of a compounding dividend name than a binary patent-expiry trade.

MRK still has operating leverage, but the near-term risk is that the market underestimates how much any Keytruda slowdown can compress sentiment even if the eventual earnings hit is manageable. The subcutaneous version helps retention, but it also creates a cannibalization/transition dynamic that can flatter the story in year one and then leave a harder compare later. That kind of bridge product reduces the cliff slope, not necessarily the valuation debate.

The contrarian miss is that “safer dividend” and “cheaper valuation” may not stay aligned if investors rotate toward balance-sheet quality and de-risked growth. NVS already proved it can absorb a major exclusivity loss without breaking the top line, which should support a lower cost of capital and multiple stability. The flip side: if the broader market keeps rewarding visible pipeline optionality over defensive yield, MRK can still outperform on a 12- to 24-month basis despite the nearer-term cliff risk.

The cleanest setup is relative value: long NVS vs short MRK into the next 6-12 months, because the spread is likely to be driven by cliff optics and dividend confidence rather than absolute earnings. If you want to own one outright, NVS offers better downside protection; MRK is the higher-beta version with more upside if the market starts paying for launch execution and pipeline monetization instead of patent risk.

Key Decisions for Investors

• Initiate long NVS / short MRK pair trade over the next 1-3 months; target 8-12% relative outperformance for NVS as capital rotates toward lower-cliff, higher-visibility cash flows.
• Add to NVS on any 3-5% pullback; use a 6-12 month horizon and expect the dividend-plus-pipeline profile to compress downside better than peers if biotech multiples stay stable.
• Hold MRK only as a tactical rebound name: buy on weakness tied to patent-expiry headlines, but size smaller because the next 12-24 months likely feature multiple compression around exclusivity transition risk.
• For options, consider a 6-9 month call spread on NVS rather than stock if you want yield-adjusted upside with defined risk; implied vol should be less punitive than the event risk embedded in MRK.
• Avoid chasing both names outright into the same theme basket; the better expression is relative value, not directional sector beta, because the real edge is in difference in cliff severity and dividend durability.